Skip to main content

Advertisement

SpringerLink
Log in

Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects

  • Review
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

Pharmacological “cognitive enhancement” (CE) is defined as the use of any psychoactive drug with the purpose of enhancing cognition, e.g. regarding attention, concentration or memory by healthy subjects. Substances commonly used as CE drugs can be categorized into three groups of drugs: (1) over-the-counter (OTC) drugs such as coffee, caffeinated drinks/energy drinks, caffeine tablets or Ginkgo biloba; (2) drugs being approved for the treatment of certain disorders and being misused for CE: drugs to treat attention-deficit/hyperactivity disorder (ADHD) such as the stimulants methylphenidate (MPH, e.g. Ritalin®) or amphetamines (AMPH, e.g. Attentin® or Adderall®), to treat sleep disorders such as modafinil or to treat Alzheimer’s disease such as acetylcholinesterase inhibitors; (3) illicit drugs such as illicit AMPH, e.g. “speed”, ecstasy, methamphetamine (crystal meth) or others. Evidence from randomized placebo-controlled trials shows that the abovementioned substances have limited pro-cognitive effects as demonstrated, e.g. regarding increased attention, increased cognitive speed or shortening of reaction times, but on the same time poses considerable safety risks on the consumers. Prevalence rates for the use of CE drugs among healthy subjects show a broad range from less than 1 % up to more than 20 %. The range in prevalence rates estimates results from several factors which are chosen differently in the available survey studies: type of subjects (students, pupils, special professions, etc.), degree of anonymity in the survey (online, face-to-face, etc.), definition of CE and substances used/misused for CE, which are assessed (OTC drugs, prescription, illicit drugs) as well as time periods of use (e.g. ever, during the past year/month/week, etc.). A clear and comprehensive picture of the drugs used for CE by healthy subjects and their adverse events and safety risks as well as comprehensive and comparable international data on the prevalence rates of CE among healthy subjects are of paramount importance for informing policy makers and healthcare professionals about CE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bagot KS, Kaminer Y (2014) Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review. Addiction 109:547–557

    Article  PubMed  Google Scholar 

  2. Benowitz NL (1990) Clinical pharmacology of caffeine. Annu Rev Med 41:277–288

    Article  PubMed  CAS  Google Scholar 

  3. Birks J, Grimley Evans J (2009) Ginkgo biloba for cognitive impairment and dementia. The Cochrane database of systematic reviews: CD003120

  4. Bukstein O (2008) Substance abuse in patients with attention-deficit/hyperactivity disorder. Medscape J Med 10:24

    PubMed  PubMed Central  Google Scholar 

  5. Burgard DA, Fuller R, Becker B, Ferrell R, Dinglasan-Panlilio MJ (2013) Potential trends in attention deficit hyperactivity disorder (adhd) drug use on a college campus: wastewater analysis of amphetamine and ritalinic acid. Sci Total Environ 450–451:242–249

    Article  PubMed  Google Scholar 

  6. Cakic V (2009) Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology. J Med Ethics 35:611–615

    Article  PubMed  CAS  Google Scholar 

  7. Campbell AA (1987) Randomized response technique. Science 236:1049

    Article  PubMed  CAS  Google Scholar 

  8. Chatterjee A (2004) Cosmetic neurology: For physicians the future is now. The virtual mentor: VM 6

  9. Deutsche Angestelltenkrankenkasse (DAK) (2009) Gesundheitsreport 2009. Analyse der Arbeitsunfähigkeitsdaten. Schwerpunktthema Doping am Arbeitsplatz. DAK Forschung, IGES Institut GmbH. Berlin/Hamburg

  10. Dietz P, Striegel H, Franke AG, Lieb K, Simon P, Ulrich R (2013) Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy 33:44–50

    Article  PubMed  Google Scholar 

  11. Fachinformation (2008) Coffeinum N 0,2 g. MERCK dura, Berlin

  12. Fachinformation (2013) Attentin 5 mg Tablette. Medice, Berlin

  13. Franke AG, Bagusat C, Dietz P, Hoffmann I, Simon P, Ulrich R, Lieb K (2013) Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons. BMC Med 11:102

    Article  PubMed  PubMed Central  Google Scholar 

  14. Franke AG, Bonertz C, Christmann M, Huss M, Fellgiebel A, Hildt E, Lieb K (2011) Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in germany. Pharmacopsychiatry 44:60–66

    Article  PubMed  CAS  Google Scholar 

  15. Franke AG, Christmann M, Bonertz C, Fellgiebel A, Huss M, Lieb K (2011) Use of coffee, caffeinated drinks and caffeine tablets for cognitive enhancement in pupils and students in germany. Pharmacopsychiatry 44:331–338

    Article  PubMed  CAS  Google Scholar 

  16. Franke AG, Heinrich I, Lieb K, Fellgiebel A (2014) The use of ginkgo biloba in healthy elderly. Age 36:435–444

    Article  PubMed  Google Scholar 

  17. Franke AG, Lieb K (2013) Pharmacological neuroenhancement: substances and epidemiology. In: Hildt E, Franke AG (eds) Cognitive enhancement—an interdisciplinary perspective. Springer, Heidelberg, pp 17–27

    Google Scholar 

  18. Franke AG, Lieb K (2010) pharmacological neuroenhancement and brain doping: chances and risks. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53:853–859

    Article  PubMed  CAS  Google Scholar 

  19. Franke AG, Lieb K, Fellgiebel A (2009) from symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of alzheimer’s disease. Fortschr Neurol Psychiatr 77:326–333

    Article  PubMed  CAS  Google Scholar 

  20. Franke AG, Bagusat C; McFarlane C, Tassone-Steiger T, Kneist W, Lieb K (2014) The use of caffeinated substances by surgeons for cognitive enhancement. Ann Surg [Epub ahead of print]

  21. Hart CL, Haney M, Vosburg SK, Comer SD, Gunderson E, Foltin RW (2006) Modafinil attenuates disruptions in cognitive performance during simulated night-shift work. Neuropsychopharmacology 31:1526–1536

    Article  PubMed  CAS  Google Scholar 

  22. Kelley AM, Webb CM, Athy JR, Ley S, Gaydos S (2012) Cognition enhancement by modafinil: a meta-analysis. Aviat Space Environ Med 83:685–690

    Article  PubMed  CAS  Google Scholar 

  23. Killgore WD, Kahn-Greene ET, Grugle NL, Killgore DB, Balkin TJ (2009) Sustaining executive functions during sleep deprivation: a comparison of caffeine, dextroamphetamine, and modafinil. Sleep 32:205–216

    PubMed  PubMed Central  Google Scholar 

  24. Killgore WD, Rupp TL, Grugle NL, Reichardt RM, Lipizzi EL, Balkin TJ (2008) Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness. J Sleep Res 17:309–321

    Article  PubMed  Google Scholar 

  25. Kollins SH (2008) A qualitative review of issues arising in the use of psycho-stimulant medications in patients with adhd and co-morbid substance use disorders. Curr Med Res Opin 24:1345–1357

    Article  PubMed  Google Scholar 

  26. Kollins SH, MacDonald EK, Rush CR (2001) Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 68:611–627

    Article  PubMed  CAS  Google Scholar 

  27. Lensvelt-Mulders G, Hox JJ, van der Heuden PG, Maas CJM (2005) Meta-analysis of randomized response research thirty-five years of validation. Sociol Method Res 33(3):319–348

    Article  Google Scholar 

  28. Lucke JC, Bell SK, Partridge BJ, Hall WD (2011) Academic doping or viagra for the brain? The history of recreational drug use and pharmacological enhancement can provide insight into these uses of neuropharmaceuticals. EMBO Rep 12:197–201

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  29. Mache S, Eickenhorst P, Vitzthum K, Klapp BF, Groneberg DA (2012) Cognitive-enhancing substance use at german universities: frequency, reasons and gender differences. Wien Med Wochenschr 162:262–271

    Article  PubMed  Google Scholar 

  30. Maher B (2008) Poll results: look who’s doping. Nature 452:674–675

    Article  PubMed  CAS  Google Scholar 

  31. McCabe SE, Boyd CJ (2005) Sources of prescription drugs for illicit use. Addict Behav 30:1342–1350

    Article  PubMed  PubMed Central  Google Scholar 

  32. McCabe SE, Knight JR, Teter CJ, Wechsler H (2005) Non-medical use of prescription stimulants among us college students: prevalence and correlates from a national survey. Addiction 100:96–106

    Article  PubMed  Google Scholar 

  33. McCabe SE, Teter CJ, Boyd CJ (2006) Medical use, illicit use and diversion of prescription stimulant medication. J Psychoactive Drugs 38:43–56

    Article  PubMed  PubMed Central  Google Scholar 

  34. McLellan TM, Lieberman HR (2012) Do energy drinks contain active components other than caffeine? Nutr Rev 70:730–744

    Article  PubMed  Google Scholar 

  35. Mehlman MJ (2004) Cognition-enhancing drugs. Milbank Q 82:483–506

    Article  PubMed  PubMed Central  Google Scholar 

  36. Middendorf E, Poskowsky J, Isserstedt W (2012) [Formen der Stresskompensation und Leistungssteigerung bei Studierenden. HISBUS-Befragung zur Verbreitung und zu Mustern von Hirndoping und Medikamentenmissbrauch.] Hannover: HIS Hochschul-Informations-System GmbH

  37. Miller KE (2008) Wired: energy drinks, jock identity, masculine norms, and risk taking. J Am Coll Health 56:481–489

    Article  PubMed  PubMed Central  Google Scholar 

  38. Morente-Sanchez J, Zabala M (2013) Doping in sport: a review of elite athletes’ attitudes, beliefs, and knowledge. Sports Med 43:395–411

    Article  PubMed  Google Scholar 

  39. Muhammed K (2014) Cosmetic neurology: the role of healthcare professionals. Med Health Care Philos 17:239–240

    Article  PubMed  Google Scholar 

  40. Nehlig A, Daval JL, Debry G (1992) Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 17:139–170

    Article  PubMed  CAS  Google Scholar 

  41. Nestle M (2000) Soft drink “pouring rights”: marketing empty calories to children. Public Health Rep 115:308–319

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  42. Oades RD, Sadile AG, Sagvolden T, Viggiano D, Zuddas A, Devoto P, Aase H, Johansen EB, Ruocco LA, Russell VA (2005) The control of responsiveness in adhd by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. Dev Sci 8:122–131

    Article  PubMed  Google Scholar 

  43. Ott R, Biller-Andorno N (2014) Neuroenhancement among swiss students–a comparison of users and non-users. Pharmacopsychiatry 47:22–28

    PubMed  CAS  Google Scholar 

  44. Partridge BJ, Bell SK, Lucke JC, Yeates S, Hall WD (2011) Smart drugs “as common as coffee”: media hype about neuroenhancement. PLoS One 6:e28416

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  45. Pendergras M (2010) Uncommon grounds: the history of coffee and how it transformed our world. Basic Books, New York

    Google Scholar 

  46. Prince J (2008) Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update. J Clin Psychopharmacol 28:S39–S45

    Article  PubMed  CAS  Google Scholar 

  47. Repantis D, Laisney O, Heuser I (2010) Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 61:473–481

    Article  PubMed  CAS  Google Scholar 

  48. Repantis D, Schlattmann P, Laisney O, Heuser I (2010) Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 62:187–206

    Article  PubMed  CAS  Google Scholar 

  49. Sattler S, Wiegel C (2013) Cognitive test anxiety and cognitive enhancement: the influence of students’ worries on their use of performance-enhancing drugs. Subst Use Misuse 48:220–232

    Article  PubMed  Google Scholar 

  50. Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R (2002) Ginkgo for memory enhancement: a randomized controlled trial. JAMA 288:835–840

    Article  PubMed  Google Scholar 

  51. Starbucks (2014) Homepage of Starbucks containing information about their products. http://www.starbucks.de. Accessed Aug 2014

  52. Sugden C, Housden CR, Aggarwal R, Sahakian BJ, Darzi A (2012) Effect of pharmacological enhancement on the cognitive and clinical psychomotor performance of sleep-deprived doctors: a randomized controlled trial. Ann Surg 255:222–227

    Article  PubMed  Google Scholar 

  53. Teter CJ, Falone AE, Cranford JA, Boyd CJ, McCabe SE (2010) Nonmedical use of prescription stimulants and depressed mood among college students: frequency and routes of administration. J Subst Abuse Treat 38:292–298

    Article  PubMed  PubMed Central  Google Scholar 

  54. Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ (2006) Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 26:1501–1510

    Article  PubMed  PubMed Central  Google Scholar 

  55. Wagner JC (1991) Enhancement of athletic performance with drugs. An overview. Sports Med 12:250–265

    Article  PubMed  CAS  Google Scholar 

  56. Wesensten NJ, Killgore WD, Balkin TJ (2005) Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J Sleep Res 14:255–266

    Article  PubMed  Google Scholar 

  57. Wilens TE (2008) Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 28:S46–S53

    Article  PubMed  CAS  Google Scholar 

  58. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo S (2008) Misuse and diversion of stimulants prescribed for adhd: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 47:21–31

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

All authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Social Work and Education, University of Neubrandenburg, University of Applied Sciences, Brodaer Str. 2, 17033, Neubrandenburg, Germany

    Andreas G. Franke

  2. Department of Psychiatry and Psychotherapy, University Medical Centre Mainz, Untere Zahlbacher Str. 8, 55131, Mainz, Germany

    Andreas G. Franke, Christiana Bagusat, Sebastian Rust, Alice Engel & Klaus Lieb

Authors
  1. Andreas G. Franke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christiana Bagusat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sebastian Rust
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alice Engel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Klaus Lieb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas G. Franke.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Franke, A.G., Bagusat, C., Rust, S. et al. Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur Arch Psychiatry Clin Neurosci 264 (Suppl 1), 83–90 (2014). https://doi.org/10.1007/s00406-014-0537-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-014-0537-1

Keywords

Search

Navigation